{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:59:00Z","timestamp":1781326740927,"version":"3.54.1"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["2232010"],"award-info":[{"award-number":["2232010"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22476011"],"award-info":[{"award-number":["22476011"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22276015"],"award-info":[{"award-number":["22276015"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21771023"],"award-info":[{"award-number":["21771023"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22076013"],"award-info":[{"award-number":["22076013"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","award":["20230484470"],"award-info":[{"award-number":["20230484470"]}],"id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejmech.2025.118400","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:34:23Z","timestamp":1764117263000},"page":"118400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Advances in radiolabelled CDK4\/6 inhibitors for in vivo imaging of CDK4\/6 activity in tumours"],"prefix":"10.1016","volume":"303","author":[{"given":"Peiwen","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangxing","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianna","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dajie","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingna","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuojie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3549-6483","authenticated-orcid":false,"given":"Junbo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6577","key":"10.1016\/j.ejmech.2025.118400_bib1","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc1495","article-title":"Cdk4 and cdk6 kinases: from basic science to cancer therapy","volume":"375","author":"Fassl","year":"2022","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.ejmech.2025.118400_bib2","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.3390\/ijms22062935","article-title":"Cyclin-dependent kinases (cdk) and their role in diseases development-review","volume":"22","author":"Lukasik","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118400_bib3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.semcancer.2023.12.002","article-title":"Beyond cell cycle regulation: the pleiotropic function of cdk4 in cancer","volume":"98","author":"Ziegler","year":"2024","journal-title":"Semin. Cancer Biol."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118400_bib4","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11906-007-0084-5","article-title":"Lipid-induced cell dysfunction and cell death: lessons from yeast","volume":"9","author":"Kohlwein","year":"2007","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.ejmech.2025.118400_bib5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12915-015-0164-y","article-title":"Pursuing the impossible: an interview with tim hunt","volume":"13","author":"Hunt","year":"2015","journal-title":"BMC Biol."},{"key":"10.1016\/j.ejmech.2025.118400_bib6","series-title":"Handbook of Cell Signaling","first-page":"2545","article-title":"Chapter 302 - regulation of cell cycle progression","author":"Scorah","year":"2010"},{"issue":"39","key":"10.1016\/j.ejmech.2025.118400_bib7","doi-asserted-by":"crossref","first-page":"9315","DOI":"10.1021\/acs.jpcb.4c03243","article-title":"Binding modalities and phase-specific regulation of cyclin\/cyclin-dependent kinase complexes in the cell cycle","volume":"128","author":"Bergman","year":"2024","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.ejmech.2025.118400_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101103","article-title":"Mechanisms of sensitivity and resistance to cdk4\/cdk6 inhibitors in hormone receptor-positive breast cancer treatment","volume":"76","author":"Glaviano","year":"2024","journal-title":"Drug Resist. Updates"},{"issue":"4","key":"10.1016\/j.ejmech.2025.118400_bib9","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.molcel.2019.03.020","article-title":"Cyclin d-cdk4,6 drives cell-cycle progression via the retinoblastoma protein's c-terminal helix","volume":"74","author":"Topacio","year":"2019","journal-title":"Mol. Cell"},{"issue":"29","key":"10.1016\/j.ejmech.2025.118400_bib10","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1038\/s41388-020-1354-9","article-title":"Senescence as a therapeutically relevant response to cdk4\/6 inhibitors","volume":"39","author":"Wagner","year":"2020","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.ejmech.2025.118400_bib11","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1349-7006.2007.00449.x","article-title":"Functions of cyclin d1 as an oncogene and regulation of cyclin d1 expression","volume":"98","author":"Tashiro","year":"2007","journal-title":"Cancer Sci."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118400_bib12","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3390\/biomedicines10030685","article-title":"Targeting cdk4\/6 for anticancer therapy","volume":"10","author":"Qi","year":"2022","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118400_bib13","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s12276-025-01395-3","article-title":"Targeting cdk4\/6 in breast cancer","volume":"57","author":"Shanabag","year":"2025","journal-title":"Exp. Mol. Med."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118400_bib14","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s13402-022-00714-4","article-title":"Applications and mechanisms of the cyclin-dependent kinase 4\/6 inhibitor, pd-0332991, in solid tumors","volume":"45","author":"Chen","year":"2022","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.ejmech.2025.118400_bib15","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ctrv.2017.09.003","article-title":"Cdk4\/6 inhibition in early and metastatic breast cancer: a review","volume":"60","author":"De Groot","year":"2017","journal-title":"Cancer Treat Rev."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118400_bib16","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting cdk4 and cdk6 in cancer","volume":"22","author":"Goel","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.ejmech.2025.118400_bib17","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00044-025-03411-7","article-title":"Pharmacological significance of palbociclib and its derivatives in cancer treatment and prevention : an update","volume":"34","author":"Shagufta","year":"2025","journal-title":"Med. Chem. Res."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118400_bib18","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40265-017-0742-0","article-title":"Ribociclib : first global approval","volume":"77","author":"Syed","year":"2017","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118400_bib19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/1060028018795146","article-title":"Abemaciclib: the newest cdk4\/6 inhibitor for the treatment of breast cancer","volume":"53","author":"Palumbo","year":"2019","journal-title":"Ann. Pharmacother."},{"issue":"7\u20138","key":"10.1016\/j.ejmech.2025.118400_bib20","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1159\/000516422","article-title":"[18F]-Fluorodeoxyglucose positron emission tomography\/ct to assess the early metabolic response in patients with hormone receptor-positive her2-negative metastasized breast cancer treated with cyclin-dependent 4\/6 kinase inhibitors","volume":"44","author":"Seifert","year":"2021","journal-title":"Oncol. Res. Treat."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118400_bib21","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.3390\/cancers15061855","article-title":"Post-cdk4\/6 inhibitor therapy: current agents and novel targets","volume":"15","author":"Ashai","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"23","key":"10.1016\/j.ejmech.2025.118400_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314534","article-title":"Biomarkers of response and resistance to cdk4\/6 inhibitors in breast cancer: hints from liquid biopsy and microrna exploration","volume":"23","author":"Krasniqi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118400_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2022.119346","article-title":"Resistance to cdk4\/6 inhibition: mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancer","volume":"1869","author":"Papadimitriou","year":"2022","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118400_bib24","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1158\/1078-0432.CCR-18-2769","article-title":"Cell-proliferation imaging for monitoring response to cdk4\/6 inhibition combined with endocrine-therapy in breast cancer: comparison of [(18)F]FLT and [(18)F]ISO-1 PET\/CT","volume":"25","author":"Elmi","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118400_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103863","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors (cdk4\/6i): mechanisms of resistance and where to find them","volume":"79","author":"Foffano","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.ejmech.2025.118400_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2009\/106378","article-title":"Cell cycle regulating kinase cdk4 as a potential target for tumor cell treatment and tumor imaging","volume":"2009","author":"Graf","year":"2009","journal-title":"J. Oncol."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118400_bib27","doi-asserted-by":"crossref","first-page":"7209","DOI":"10.1007\/s13277-014-1884-2","article-title":"Cyclin-dependent kinase 4 overexpression is mostly independent of gene amplification and constitutes an independent prognosticator for nasopharyngeal carcinoma","volume":"35","author":"Chen","year":"2014","journal-title":"Tumor Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118400_bib28","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12032-012-0379-5","article-title":"Clinical implications of deregulated cdk4 and cyclin d1 expression in patients with human hepatocellular carcinoma","volume":"30","author":"Lu","year":"2013","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ejmech.2025.118400_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1148792","article-title":"Cdk4\/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective","volume":"11","author":"Zhou","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118400_bib30","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3390\/diagnostics13050987","article-title":"Mechanisms of resistance to cdk4\/6 inhibitors and predictive biomarkers of response in hr+\/her2-metastatic breast cancer-a review of the literature","volume":"13","author":"Stanciu","year":"2023","journal-title":"Diagnostics"},{"issue":"5","key":"10.1016\/j.ejmech.2025.118400_bib31","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.cell.2020.10.036","article-title":"Proteogenomic landscape of breast cancer tumorigenesis and targeted therapy","volume":"183","author":"Krug","year":"2020","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.ejmech.2025.118400_bib32","doi-asserted-by":"crossref","first-page":"10905","DOI":"10.18632\/oncotarget.23649","article-title":"Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in braf (v600e) -mutant melanoma","volume":"9","author":"Harris","year":"2018","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.ejmech.2025.118400_bib33","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1016\/j.clbc.2021.08.007","article-title":"The effects of her2 on cdk4\/6 activity in breast cancer","volume":"22","author":"Sinclair","year":"2022","journal-title":"Clin. Breast Cancer"},{"issue":"7","key":"10.1016\/j.ejmech.2025.118400_bib34","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1158\/1535-7163.MCT-24-0856","article-title":"18F-FLT PET, a non-invasive pharmacodynamic biomarker of tumor cell proliferation, detected differential response to various cyclin dependent kinase (cdk) inhibitors","volume":"24","author":"Giddabasappa","year":"2025","journal-title":"Mol. Cancer Ther."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118400_bib35","doi-asserted-by":"crossref","first-page":"12655","DOI":"10.1007\/s13277-016-5167-y","article-title":"P16 upregulation is linked to poor prognosis in erg negative prostate cancer","volume":"37","author":"Burdelski","year":"2016","journal-title":"Tumour Biol"},{"issue":"12","key":"10.1016\/j.ejmech.2025.118400_bib36","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s12149-023-01871-8","article-title":"(18)F-FES and (18)F-FDG PET\/CT imaging as a predictive biomarkers for metastatic breast cancer patients undergoing cyclin-dependent 4\/6 kinase inhibitors with endocrine treatment","volume":"37","author":"Liu","year":"2023","journal-title":"Ann. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.118400_bib37","series-title":"Future Data and Security Engineering. Big Data, Security and Privacy, Smart City and Industry 4.0 Applications","first-page":"103","article-title":"Detection and evaluation of ki-67 proliferation index of breast cancer cells using deep learning technique","author":"Phan","year":"2024"},{"issue":"6","key":"10.1016\/j.ejmech.2025.118400_bib38","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1007\/s00259-024-07058-1","article-title":"Predictive and prognostic value of (18)F-FES PET\/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4\/6 inhibitors","volume":"52","author":"Jeong","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejmech.2025.118400_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1454844","article-title":"The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4\/6 inhibitors in the second-line setting","volume":"14","author":"Kubeczko","year":"2024","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118400_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105079","article-title":"Precision oncology in biliary tract cancer : the emerging role of liquid biopsy","volume":"10","author":"De Scordilli","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejmech.2025.118400_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104776","article-title":"Cancer in a drop : advances in liquid biopsy in 2024","volume":"213","author":"Borea","year":"2025","journal-title":"Crit. Rev. Oncol. Hemat."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118400_bib42","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.addr.2008.04.013","article-title":"Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer","volume":"60","author":"Hamoudeh","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118400_bib43","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1053\/j.semnuclmed.2013.02.001","article-title":"Hybrid imaging worldwide-challenges and opportunities for the developing world: a report of a technical meeting organized by iaea","volume":"43","author":"Kashyap","year":"2013","journal-title":"Semin. Nucl. Med."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118400_bib44","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s12149-025-02031-w","article-title":"Deep learning in nuclear medicine: from imaging to therapy","volume":"39","author":"Zhang","year":"2025","journal-title":"Ann. Nucl. Med."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118400_bib45","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1053\/j.semnuclmed.2019.06.004","article-title":"Novel target selection for nuclear medicine studies","volume":"49","author":"Lee","year":"2019","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.118400_bib46","series-title":"Handbook of Particle Detection and Imaging","first-page":"857","article-title":"Radiation-based medical imaging techniques: an overview","author":"Prior","year":"2012"},{"issue":"4","key":"10.1016\/j.ejmech.2025.118400_bib47","first-page":"429","article-title":"Nuclear medicine in oncology","volume":"6","author":"Oliveira","year":"2018","journal-title":"Comput. Methods Biomech. Biomed. Eng.: Imaging & Visualization"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118400_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1109\/TRPMS.2019.2908633","article-title":"Parametric imaging with PET and SPECT","volume":"4","author":"Gallezot","year":"2020","journal-title":"Ieee Transactions On Radiation and Plasma Medical Sciences"},{"issue":"1150","key":"10.1016\/j.ejmech.2025.118400_bib49","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20211126","article-title":"The role of clinical imaging in oncology drug development: progress and new challenges","volume":"96","author":"Murphy","year":"2023","journal-title":"Br. J. Radiol."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118400_bib50","doi-asserted-by":"crossref","first-page":"582","DOI":"10.2174\/1389450116666150330113747","article-title":"PET and SPECT imaging for the acceleration of anti-cancer drug development","volume":"16","author":"Hillyar","year":"2015","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejmech.2025.118400_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1095779","article-title":"Case report: (18)F-FES PET\/CT predicted treatment responses of second-line and third-line cdk4\/6 inhibitors after disease progression on first-line cdk4\/6 inhibitor in a hr+\/her2- metastatic breast cancer patient","volume":"12","author":"Pan","year":"2022","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118400_bib52","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2967\/jnumed.124.268984","article-title":"Intrapatient 16 alpha-[(18)F]Fluoro-17 beta-estradiol PET heterogeneity as a prognostic factor for endocrine therapy response and survival in patients with estrogen receptor-positive metastatic breast cancer","volume":"66","author":"Van Geel","year":"2025","journal-title":"J. Nucl. Med."},{"issue":"31","key":"10.1016\/j.ejmech.2025.118400_bib53","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1200\/JCO.22.00400","article-title":"Clinical validity of 16 alpha-[(18)F]Fluoro-17 beta-estradiol positron emission tomography\/computed tomography to assess estrogen receptor status in newly diagnosed metastatic breast cancer","volume":"40","author":"Van Geel","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118400_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058938","article-title":"Limits of [18F]-FLT PET as a biomarker of proliferation in oncology","volume":"8","author":"Mckinley","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118400_bib55","first-page":"95","article-title":"Applications of PET imaging with the proliferation marker [18F]-FLT","volume":"59","author":"Peck","year":"2015","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118400_bib56","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7150\/thno.16676","article-title":"Preclinical applications of 3'-deoxy-3'-[(18)F]Fluorothymidine in oncology - a systematic review","volume":"7","author":"Schelhaas","year":"2017","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/j.ejmech.2025.118400_bib57","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s12149-021-01603-w","article-title":"(18)F-FLT PET\/CT imaging for early monitoring response to cdk4\/6 inhibitor therapy in triple negative breast cancer","volume":"35","author":"Ma","year":"2021","journal-title":"Ann. Nucl. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118400_bib58","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/s12967-022-03580-8","article-title":"3'-[(18)F]Fluoro-3'-deoxythymidine ([(18)F]FLT) positron emission tomography as an in vivo biomarker of inhibition of cdk4\/6-rb pathway by palbociclib in a patient derived bladder tumor","volume":"20","author":"Tatum","year":"2022","journal-title":"J. Transl. Med."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118400_bib59","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1021\/acs.jmedchem.0c02265","article-title":"Recent advances in the development of sigma receptor ligands as cytotoxic agents : a medicinal chemistry perspective","volume":"64","author":"Fallica","year":"2021","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118400_bib60","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1535-7163.MCT-19-0253","article-title":"The ongoing search for biomarkers of cdk4\/6 inhibitor responsiveness in breast cancer","volume":"19","author":"Schoninger","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118400_bib61","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3390\/molecules28030931","article-title":"Recent developments in carbon-11 chemistry and applications for first-in-human PET studies","volume":"28","author":"Pees","year":"2023","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.ejmech.2025.118400_bib62","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s11307-018-1163-5","article-title":"From carbon-11-labeled amino acids to peptides in positron emission tomography : the synthesis and clinical application","volume":"20","author":"Pekoak","year":"2018","journal-title":"Mol. Imaging Biol."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118400_bib63","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.addr.2010.09.007","article-title":"Radiopharmaceutical chemistry for positron emission tomography","volume":"62","author":"Li","year":"2010","journal-title":"Adv. Drug Deliver. Rev."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118400_bib64","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2174\/138955710791384072","article-title":"Cyclin-dependent kinase 4\/6 (cdk4\/6) inhibitors: perspectives in cancer therapy and imaging","volume":"10","author":"Graf","year":"2010","journal-title":"Mini-Rev. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118400_bib65","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2967\/jnumed.119.232603","article-title":"Noninvasive PET imaging of cdk4\/6 activation in breast cancer","volume":"61","author":"Ramos","year":"2020","journal-title":"J. Nucl. Med."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118400_bib66","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1021\/acs.molpharmaceut.3c00216","article-title":"Preparation and evaluation of [(18)F]AlF-NOTA-PBB for PET imaging of cyclin-dependent kinase 4\/6 in tumors","volume":"20","author":"Xiao","year":"2023","journal-title":"Mol. Pharm."},{"issue":"13","key":"10.1016\/j.ejmech.2025.118400_bib67","doi-asserted-by":"crossref","first-page":"6870","DOI":"10.3390\/ijms25136870","article-title":"Development of a radiolabeled cyclin-dependent kinases 4 and 6 (cdk4\/6) inhibitor for brain and cancer PET imaging","volume":"25","author":"Huang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"47","key":"10.1016\/j.ejmech.2025.118400_bib68","doi-asserted-by":"crossref","first-page":"32253","DOI":"10.1021\/acsomega.1c05073","article-title":"Gallium-68 labeling of the cyclin-dependent kinase 4\/6 inhibitors as positron emission tomography radiotracers for tumor imaging","volume":"6","author":"Liu","year":"2021","journal-title":"ACS Omega"},{"issue":"6","key":"10.1016\/j.ejmech.2025.118400_bib69","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1021\/acsmedchemlett.4c00116","article-title":"Synthesis and preclinical evaluation of novel (68)Ga-DOTA-RBB as potential PET radiotracer for imaging cdk4\/6 in tumors","volume":"15","author":"Yu","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118400_bib70","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1021\/acs.jmedchem.4c02672","article-title":"Imaging cdk4\/6 broaden options of breast cancer diagnostics with positron emission tomography","volume":"68","author":"Ji","year":"2025","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118400_bib71","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF02985098","article-title":"Single-photon agents for tumor imaging: 201Tl, 99mTc-mibi, and 99mTc-tetrofosmin","volume":"18","author":"Fukumoto","year":"2004","journal-title":"Ann. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.118400_bib72","series-title":"Reference Module in Neuroscience and Biobehavioral Psychology","first-page":"861","article-title":"Single photon emission computed tomography","author":"Newberg","year":"2017"},{"key":"10.1016\/j.ejmech.2025.118400_bib73","series-title":"Nuclear Medicine and Molecular Imaging","first-page":"79","article-title":"Technetium-99m radiopharmaceuticals\u2014radiochemistry and radiolabeling","author":"Cleynhens","year":"2022"},{"issue":"12","key":"10.1016\/j.ejmech.2025.118400_bib74","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.3390\/app9122526","article-title":"A picture of modern Tc-99m radiopharmaceuticals : production, chemistry, and applications in molecular imaging","volume":"9","author":"Boschi","year":"2019","journal-title":"Applied Sciences-Basel"},{"issue":"10","key":"10.1016\/j.ejmech.2025.118400_bib75","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1007\/s00259-010-1390-8","article-title":"A review on the clinical uses of SPECT\/CT","volume":"37","author":"Mariani","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. I."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118400_bib76","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1021\/acs.molpharmaceut.9b00540","article-title":"Synthesis and biological evaluation of novel (99m)Tc-labeled palbociclib derivatives targeting cyclin-dependent kinase 4\/6 (cdk4\/6) as potential cancer imaging agents","volume":"16","author":"Song","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2025.118400_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.112032","article-title":"Preparation and evaluation of (99m)Tc-labeled hynic-palbociclib analogs for cyclin-dependent kinase 4\/6-positive tumor imaging","volume":"188","author":"Gan","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118400_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117264","article-title":"Novel technetium-99m-labelled ribociclib isocyanide derivatives for imaging cyclin-dependent kinase 4\/6 (cdk4\/6) expression in cancer","volume":"286","author":"Han","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118400_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1212986","article-title":"Differences in metabolic transport and resistance mechanisms of abemaciclib, palbociclib, and ribociclib","volume":"14","author":"Zhu","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"15","key":"10.1016\/j.ejmech.2025.118400_bib80","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1016\/j.bmcl.2008.06.027","article-title":"Imidazole piperazines: sar and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode","volume":"18","author":"Finlay","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118400_bib81","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.2967\/jnumed.117.205088","article-title":"Radioiodinated small-molecule tyrosine kinase inhibitor for HER2-selective SPECT imaging","volume":"59","author":"Tang","year":"2018","journal-title":"J. Nucl. Med."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118400_bib82","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1002\/cmdc.201200264","article-title":"Fluorine-18 radiolabeling and radiopharmacological characterization of a benzodioxolylpyrimidine-based radiotracer targeting the receptor tyrosine kinase EphB4","volume":"7","author":"Mamat","year":"2012","journal-title":"ChemMedChem"},{"issue":"11","key":"10.1016\/j.ejmech.2025.118400_bib83","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1021\/acs.molpharmaceut.7b00536","article-title":"Development of a new fr-targeting agent (99m)Tc-hynfa with improved imaging contrast and comparison of multimerization and\/or pegylation strategies for radio-folate modification","volume":"14","author":"Guo","year":"2017","journal-title":"Mol. Pharm."},{"issue":"8015","key":"10.1016\/j.ejmech.2025.118400_bib84","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41586-024-07461-6","article-title":"Covalent targeted radioligands potentiate radionuclide therapy","volume":"630","author":"Cui","year":"2024","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ejmech.2025.118400_bib85","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1007\/s11426-025-2555-x","article-title":"Covalent multi-targeted radiopharmaceuticals for enhanced tumor theranostics","volume":"68","author":"Guo","year":"2025","journal-title":"Sci. China Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118400_bib86","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1039\/C2MD20180A","article-title":"Approaches to discover non-ATP site kinase inhibitors","volume":"4","author":"Gavrin","year":"2013","journal-title":"Medchemcomm"},{"issue":"17","key":"10.1016\/j.ejmech.2025.118400_bib87","doi-asserted-by":"crossref","first-page":"7667","DOI":"10.1021\/jacs.1c12935","article-title":"Stimuli-responsive macrocyclization scaffold allows in situ self-assembly of radioactive tracers for positron emission tomography imaging of enzyme activity","volume":"144","author":"Lin","year":"2022","journal-title":"J. Am. Chem. Soc."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118400_bib88","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.7150\/thno.11758","article-title":"Enzyme-controlled intracellular self-assembly of (18)F nanoparticles for enhanced microPET imaging of tumor","volume":"5","author":"Liu","year":"2015","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/j.ejmech.2025.118400_bib89","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1039\/D4MD00591K","article-title":"Enhancing the radionuclide theranostic concept through the radiohybrid approach","volume":"16","author":"Kronke","year":"2025","journal-title":"RSC Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425011651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425011651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:54:31Z","timestamp":1781326471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425011651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":89,"alternative-id":["S0223523425011651"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118400","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in radiolabelled CDK4\/6 inhibitors for in vivo imaging of CDK4\/6 activity in tumours","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118400","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118400"}}